المؤلفون: Lara, Primo N, Moon, James, Redman, Mary W, Semrad, Thomas J, Kelly, Karen, Allen, Jeffrey, Gitlitz, Barbara, Mack, Philip C, Gandara, David R

المصدر: Clinical Lung Cancer. 17(2)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Lung, Clinical Research, Lung Cancer, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Small Cell, Databases, Factual, Female, Humans, L-Lactate Dehydrogenase, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Patient Outcome Assessment, Platinum Compounds, Prognosis, Prospective Studies, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Survival Analysis, Therapies, Investigational, Topotecan, Treatment Outcome, Young Adult, Clinical trials, Disease control rate, Landmark analysis, Outcomes, Small-cell lung cancer, Targeted therapy, Tumor assessment, Clinical Sciences, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis

الوصف: BackgroundOverall response rate is frequently used as an end point in phase 2 trials of platinum-treated extensive stage (ES) small-cell lung cancer (SCLC). We hypothesized that disease control rate (DCR) would be a superior surrogate for subsequent survival outcomes.MethodsUpdated patient-level data from Southwest Oncology Group (SWOG) trials in second- and/or third-line ES-SCLC patients were pooled. Landmark analysis was performed among patients alive at 8 weeks for overall survival (OS) measured from the 8-week landmark. Association of clinical prognostic factors with DCR was assessed using logistic regression. A Cox proportional hazard model was used to assess the associations between DCR at the landmark time and subsequent OS, adjusted for prognostic factors.ResultsOf the 319 ES-SCLC patients, 263 were alive at the 8-week landmark and constituted the pooled study population. Only 8 patients had a response. Disease control at 8 weeks was seen in 98 patients. Bivariate analysis of OS from the 8-week landmark revealed that DCR (hazard ratio [HR], 0.47; P < .0001) and elevated lactate dehydrogenase (HR, 1.70; P = .0004) were significantly associated with OS. In multivariable analysis, DCR remained an independent predictor of subsequent survival from the 8-week landmark (HR, 0.50; P < .0001).ConclusionIn this large second- and third-line ES-SCLC database, DCR at 8 weeks was found to be a significant predictor of subsequent survival in patients receiving investigational therapy. These results have critical implications in the selection of surrogate end points in future prospective ES-SCLC trials.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/50n8x82cTest

المؤلفون: Pamela Pizzutilo, V. Lamorgese, D. Bafunno, Sara Elena Rebuzzi, Vittoria Lapadula, Arsela Prelaj, Vito Longo, Domenico Galetta, Niccolò Varesano, Massimo Bilancia, F. Pesola, P. Petrillo, Annamaria Catino, A. Mastrandrea, Michele Montrone, Donatella Ricci, Gabriella Del Bene, Flavio Cassano

المصدر: Clinical Lung Cancer. 21:365-377.e5

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Lung Neoplasms, Multivariate analysis, Neutrophils, medicine.medical_treatment, Lymphocyte, NSCLC, Prognostic score, chemistry.chemical_compound, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Leukocytes, Lymphocytes, Aged, 80 and over, Prognostic factor, Score, Middle Aged, Prognosis, Survival Rate, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Female, Immunotherapy, Algorithms, Adult, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Peripheral blood, 03 medical and health sciences, Internal medicine, Lactate dehydrogenase, Biomarkers, Tumor, medicine, Humans, Lung cancer, Aged, Retrospective Studies, Performance status, business.industry, IO, Eosinophil, medicine.disease, 030104 developmental biology, chemistry, business, Follow-Up Studies

الوصف: Background Second-line immunotherapy (IO) has shown an overall survival benefit. However, only 18% to 20% of patients with advanced non–small-cell lung cancer (aNSCLC) will respond, with a median progression-free survival (PFS) of 2 to 4 months. Thus, biomarkers to select those patients most likely to benefit from IO are greatly needed. Patients and Methods We conducted a retrospective analysis of 154 patients with aNSCLC who had received anti–programmed cell death 1 therapy as second line or further treatment. We assessed the absolute neutrophil, lymphocyte, monocyte, and eosinophil counts at baseline (T0) and the second (T1) and third (T2) cycles. The neutrophil/lymphocyte ratio (NLR), derived-NLR (dNLR), lymphocyte/monocyte ratio (LMR), and their percentage of change at T1 and T2 compared with T0 were evaluated. The clinical characteristics and lactate dehydrogenase (LDH) level were also considered. Univariate and multivariate analyses were performed. Significant biomarkers for PFS on multivariate analysis were combined in a prognostic score. Results For overall survival, the negative prognostic biomarkers were Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2, NLR at T0, and dNLR at T1; the LMR at T0, T1, and T2 was identified as a positive prognostic biomarker. For PFS, the negative prognostic biomarkers were ECOG PS 2, liver metastases, NLR at T0, dNLR at T1 and T2, and ≥ 30% increase of NLR from T0 to T1; the positive prognostic biomarkers were heavy smoking, LDH, and LMR at T2. The ≥ 30% increase of LMR from T0 to T1 and T0 to T2 correlated with the overall response rate. A prognostic score (EPSILoN score; smoking, ECOG PS, liver metastases, LDH, NLR) identified 3 prognostic groups (median PFS, 10.2, 4.9, and 1.7 months, respectively; P Conclusions The EPSILoN score combines 5 baseline clinical and blood biomarkers and can help to identify patients with aNSCLC who will most likely benefit from second-line IO. Further studies are warranted.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96b37277141d26eb40b72575710e1076Test
https://doi.org/10.1016/j.cllc.2019.11.017Test

المؤلفون: Jung Oh Kim, Ie Ryung Yoo, Suk Hee Hong, Sang Hoon Chun, Seung Joon Kim, Young Kyoon Kim, Jieun Lee, Jin Hyoung Kang, Chan Kwon Jung, Eun Kyung Jeon, Yeon Shil Kim, Woo Hee Choi

المصدر: Clinical Lung Cancer. 15:e13-e21

مصطلحات موضوعية: Adult, Male, Pulmonary and Respiratory Medicine, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Standardized uptake value, Multimodal Imaging, Gastroenterology, Immunoenzyme Techniques, chemistry.chemical_compound, Fluorodeoxyglucose F18, Internal medicine, Lactate dehydrogenase, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Medicine, Lung cancer, Etoposide, Aged, Neoplasm Staging, Aged, 80 and over, Cisplatin, Glucose Transporter Type 1, business.industry, Hazard ratio, Glucose transporter, Chemoradiotherapy, Middle Aged, Hypoxia-Inducible Factor 1, alpha Subunit, Prognosis, medicine.disease, Small Cell Lung Carcinoma, Primary tumor, Survival Rate, Proto-Oncogene Proteins c-bcl-2, Oncology, chemistry, Positron-Emission Tomography, Female, Radiopharmaceuticals, Tomography, X-Ray Computed, business, Nuclear medicine, Follow-Up Studies, medicine.drug

الوصف: Background Limited disease small-cell lung cancer responds well to concurrent chemoradiation therapy (CCRT), but shows high relapse rate and short RFS. We aimed to evaluate tumor metabolic activities measured using FDG-PET as a prognostic factor and analyze its relationships with markers of tumor biologic behavior. Patients and Methods Forty-one LD-SCLC patients receiving 4 cycles of EP (etoposide 120 mg/m 2 , days 1-3; cisplatin 60 mg/m 2 , day 1), 2 cycles of EP (etoposide 130 mg/m 2 , days 1-3; cisplatin 30 mg/m 2 , day 1)-CCRT were enrolled. Maximum standardized uptake value (SUV; SUVmax) of primary tumor was revised with SUV of liver (SUVlivermax). Differences between pre-, posttreatment average SUV uptake of primary tumor, and intrathoracic lymph nodes were presented as ΔSUVliveravg. Thirty-one tumor biopsy specimens were immunostained for GLUT-1, Bcl-2, and HIF-1α. Results The median overall survival (OS), and RFS were 13.7 and 10.4 months, respectively. In multivariate analysis, pretreatment lactate dehydrogenase (LDH) and ΔSUVliveravg correlated with RFS (hazard ratio [HR], 2.8, P = .043; HR, 0.3, P = .004). Sex, LDH, objective tumor metabolic response, and SUVlivermax correlated with OS (HR, 12.1, P = .006; HR, 3.7, P = .037; HR, 10.1, P = .008; and HR, 0.2, P = .014, respectively). High GLUT-1 positivity (> 75%), and LDH level (> 400 U/L) correlated with better objective response rate ( P = .012) and HIF-1α immunoreactivity score ( P = .029). Conclusion ΔSUVliveravg and GLUT-1 expression might predict RFS and ORR in patients with LD-SCLC treated with definitive CCRT.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed55d9a5e92a28daa138029af90069dTest
https://doi.org/10.1016/j.cllc.2013.09.005Test

المؤلفون: Hidekazu Suzuki, Naoko Morishita, Morita Satomu, Osamu Morimura, Norio Okamoto, Ichiro Kawase, Tomonori Hirashima, Takashi Nakasuji, Motohiro Tamiya, Masashi Kobayashi, Okafuji Kohei, Tomomi Yasue, Shiroyama Takayuki, Shinji Sasada

المصدر: Clinical Lung Cancer. 14:50-54

مصطلحات موضوعية: Adult, Male, Pulmonary and Respiratory Medicine, Cancer Research, medicine.medical_specialty, Pathology, Lung Neoplasms, Bone Neoplasms, Gastroenterology, Collagen Type I, Young Adult, Sex Factors, N-terminal telopeptide, Carcinoma, Non-Small-Cell Lung, Internal medicine, Biomarkers, Tumor, Confidence Intervals, medicine, Carcinoma, Humans, Lung cancer, Survival rate, Aged, Neoplasm Staging, Proportional Hazards Models, Aged, 80 and over, Predictive marker, L-Lactate Dehydrogenase, Performance status, business.industry, Cancer, Middle Aged, Alkaline Phosphatase, medicine.disease, Survival Rate, Oncology, Multivariate Analysis, Adenocarcinoma, Female, Peptides, business, human activities

الوصف: Lung cancer is the leading cause of cancer-related death. Many patients with lung cancer are in its advanced stages at the time of diagnosis. The 5-year survival rate for lung cancer is 10% to 20%, and the prognosis for patients with lung cancer is still poor. The crosslinked N-terminal telopeptide of type I collagen (NTx) is a metabolite of type I collagen, the main constituent of bone matrix.We measured serum NTx levels in patients who underwent staging during hospitalization for the initial treatment of lung cancer in our department. We examined whether serum NTx levels would be relevant to the prognosis of non-small-cell lung cancer (NSCLC).This study included 176 patients with lung cancer (125 men and 51 women), including 109 with adenocarcinoma, 53 with squamous cell carcinoma, 6 with large-cell carcinoma, and 8 with other cancer types. Univariate and multivariate analysis using the Cox proportional hazards model revealed a particularly close association between sex, performance status, disease stage, and serum NTx levels and overall survival (OS). A median OS of 368 days was observed for patients with a serum NTx level22 nmol BCE/L, which was significantly longer than the 197 days for patients with a serum NTx level ≥ 22 nmol BCE/L (hazard ratio [HR], 2.02; 95% confidence interval [CI], 1.36-2.99; log-rank P = .00037).We have revealed that a high serum NTx level (22 nmol BCE/L) appears to be a risk factor for a reduction in OS in patients with NSCLC.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b6c046ce418b44bde742cf63dacd0b6Test
https://doi.org/10.1016/j.cllc.2012.03.012Test

المؤلفون: Guangwei Yang, Yan Huang, Tao Qin, Yuanyuan Zhao, Yunpeng Yang, Hongyun Zhao, Wenfeng Fang, Ting Zhou, Zhibin Cheng, Xiaobo He, Shaodong Hong, Zhihuang Hu, Li Zhang, Jianhua Zhan, Yuxiang Ma

المصدر: Clinical lung cancer. 16(6)

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Inflammation, Severity of Illness Index, Prognostic score, chemistry.chemical_compound, Young Adult, Predictive Value of Tests, Lactate dehydrogenase, Internal medicine, medicine, Carcinoma, Humans, In patient, Carcinoma, Small Cell, Lung cancer, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, business.industry, Cancer, respiratory system, Middle Aged, medicine.disease, Prognosis, Survival Analysis, respiratory tract diseases, Surgery, chemistry, Biomarker (medicine), Female, medicine.symptom, business, Follow-Up Studies

الوصف: This report is the first to use the value of the Advanced Lung Cancer Inflammation Index (ALI) to predict the overall survival in patients with small-cell lung cancer. We enrolled 365 patients who were eligible for analysis and found that lower ALI was significantly associated with worse overall survival in small-cell lung cancer patients. The results showed that evaluation using ALI could authenticate the patients with poor prognosis and be a useful prognostic marker in clinical practice.A recent study indicated that the Advanced Lung Cancer Inflammation Index (ALI) could predict overall survival (OS) in patients with non-small-cell lung cancer. However, the prognostic value in small-cell lung cancer (SCLC) has not been studied. Therefore, the aim of this study was to explore the relationship between ALI and the prognosis of SCLC.We screened 460 patients who were diagnosed with SCLC from June 2006 to December 2011 in Sun Yat-Sen University Cancer Center. Data acquisition was through patients' medical information, and blood results recorded at the time of diagnosis. ALI was calculated as the formula: body mass index × serum albumin/neutrophil-lymphocyte ratio.In total, 365 patients were enrolled in this study. Patients were allocated to 2 groups: ALI19.5 (n = 60) and ALI ≥ 19.5 (n = 305). For patients with ALI19.5 and ≥ 19.5, the median OS was 10.97 and 20.14 months, respectively (P.001). On multivariate analysis, clinical stage (P.001), performance status (P = .001), lactate dehydrogenase (P.001), and ALI (P = .005) were all independent prognostic factors for OS.The results of this study demonstrated that lower ALI was significantly associated with worse OS in SCLC patients. The evaluation of ALI could authenticate the patients with poor prognosis and be a useful prognostic marker in clinical practice.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b69530dbf937c173c2b4be69a0bc2ddTest
https://pubmed.ncbi.nlm.nih.gov/25922292Test

المؤلفون: Thomas J. Semrad, Philip C. Mack, James Moon, Karen Kelly, Primo N. Lara, Barbara J. Gitlitz, Mary W. Redman, Jeffrey Warren Allen, David R. Gandara

المصدر: Lara, PN; Moon, J; Redman, MW; Semrad, TJ; Kelly, K; Allen, J; et al.(2016). Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results from the Southwest Oncology Group (SWOG) Database. Clinical Lung Cancer, 17(2), 113-118. doi: 10.1016/j.cllc.2015.09.003. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/50n8x82cTest
Clinical lung cancer, vol 17, iss 2

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Tumor assessment, Lung Neoplasms, Databases, Factual, Investigational, Platinum Compounds, computer.software_genre, Targeted therapy, Clinical trials, 0302 clinical medicine, Landmark analysis, Receptors, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Medicine, Disease control rate, Prospective Studies, Carcinoma, Small Cell, Prospective cohort study, Lung, Cancer, Aged, 80 and over, Database, Vascular Endothelial Growth Factor, Therapies, Investigational, Lung Cancer, Hazard ratio, Middle Aged, Prognosis, humanities, Treatment Outcome, 030220 oncology & carcinogenesis, Population study, Female, Adult, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Recombinant Fusion Proteins, Clinical Sciences, Oncology and Carcinogenesis, Outcomes, Small-cell lung cancer, Article, Databases, Young Adult, 03 medical and health sciences, Clinical Research, Internal medicine, Humans, Oncology & Carcinogenesis, Extensive stage, Lung cancer, Factual, Survival analysis, Aged, Neoplasm Staging, L-Lactate Dehydrogenase, business.industry, Proportional hazards model, Carcinoma, Small Cell, medicine.disease, Survival Analysis, Patient Outcome Assessment, Clinical trial, Receptors, Vascular Endothelial Growth Factor, 030104 developmental biology, Therapies, Topotecan, business, computer

الوصف: © 2016 Elsevier Inc. Background Overall response rate is frequently used as an end point in phase 2 trials of platinum-treated extensive stage (ES) small-cell lung cancer (SCLC). We hypothesized that disease control rate (DCR) would be a superior surrogate for subsequent survival outcomes. Methods Updated patient-level data from Southwest Oncology Group (SWOG) trials in second- and/or third-line ES-SCLC patients were pooled. Landmark analysis was performed among patients alive at 8 weeks for overall survival (OS) measured from the 8-week landmark. Association of clinical prognostic factors with DCR was assessed using logistic regression. A Cox proportional hazard model was used to assess the associations between DCR at the landmark time and subsequent OS, adjusted for prognostic factors. Results Of the 319 ES-SCLC patients, 263 were alive at the 8-week landmark and constituted the pooled study population. Only 8 patients had a response. Disease control at 8 weeks was seen in 98 patients. Bivariate analysis of OS from the 8-week landmark revealed that DCR (hazard ratio [HR], 0.47; P

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b94c08f9baa1812fd92ce4d43c6fd3c0Test
https://doi.org/10.1016/j.cllc.2015.09.003Test